{"id":"quetiapine-risperidone-fluphenazine","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Sedation"},{"rate":"10-30","effect":"Weight gain"},{"rate":"5-25","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"10-20","effect":"Metabolic syndrome (hyperglycemia, dyslipidemia)"},{"rate":"10-40","effect":"Prolactin elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine, risperidone, and fluphenazine are antipsychotic medications that work primarily by antagonizing dopamine D2 receptors in the brain, which reduces positive symptoms of psychosis such as hallucinations and delusions. Quetiapine and risperidone (atypical antipsychotics) also block serotonin 5-HT2A receptors, which may contribute to mood stabilization and reduced extrapyramidal side effects compared to fluphenazine (a typical antipsychotic). The combination or comparative study of these agents likely aims to optimize efficacy and tolerability profiles.","oneSentence":"These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:03.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"},{"name":"Acute agitation or psychosis"}]},"trialDetails":[{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT00161018","phase":"PHASE3","title":"New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT00014001","phase":"PHASE4","title":"CATIE- Schizophrenia Trial","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2000-12","conditions":"Schizophrenia","enrollment":1600},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Quetiapine, Risperidone, Fluphenazine","genericName":"Quetiapine, Risperidone, Fluphenazine","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Acute agitation or psychosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}